Justin M. Balko
Vanderbilt University Medical Center
232 Papers
531 Citations
Justin M. Balko is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 54, co-authored 172 publications. Previous affiliations of Justin M. Balko include The Breast Cancer Research Foundation & Vanderbilt University.
Chat about Author
Papers
Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?
TL;DR: Multivariate Cox proportional hazards modeling is used to determine that both DDX1 mRNA expression andDDX1 cytoplasmic staining are independently predictive of the commonly used markers estrogen receptor, progesterone receptor, and histological grade.
12
The genomic map of breast cancer: which roads lead to better targeted therapies?
Justin M. Balko,Justin M. Balko,Thomas Stricker,Thomas Stricker,Carlos L. Arteaga,Carlos L. Arteaga +5 more
TL;DR: These studies differed in the methods, patient cohorts, and analytical techniques employed and represent complementary snapshots of the molecular underpinnings of breast cancer.
12
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.
TL;DR: A review of the state of the field with a focus on therapeutic biomarkers and toxicities from immune checkpoint inhibitors is provided in this paper , where the authors review the state-of-the-art in this area.
11
Combined MEK and EGFR inhibition demonstrates synergistic activity in EGFR-dependent NSCLC
Justin M. Balko,Brett R. Jones,Virginia L. Coakley,Esther P. Black +3 more
- 01 Jan 2009
TL;DR: EGFR-dependent NSCLC cell lines are moderately sensitive to loss of ERK1/2 activity, either by small molecule inhibition or by siRNA knockdown, and when MEK inhibition was combined with EGFR inhibitors, cytotoxic synergy was observed for all EGFR- dependent cell lines tested in serum-containing media.
11
MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.
Justin M. Balko,Douglas B. Johnson,Daniel Ying Wang,Paula I. Ericsson-Gonzalez,Mellissa J. Nixon,Roberto Salgado,Violeta Sanchez,Daniel M. Schreeder,Ju Young Kim,Jennifer Bordeaux,Melinda E. Sanders,Randall S. Davis +11 more
TL;DR: To determine the functional effect of MHC-II on tumor cells, the authors generated isogenic M HC-II+ mouse tumors and assessed immune responsiveness and efficacy of checkpoi...
9